The telomerase inhibitor imetelstat in patients (pts) with intermediate-2 or high-risk myelofibrosis (MF) previously treated with Janus kinase (JAK) inhibitor: A phase 2, randomized study.
Year: 2016
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Ayalew Tefferi, Naseema Gangat, Dietger Niederwieser, Jan Van Droogenbroeck, Maria R. Baer, Jean-Jacques Kiladjian, Ronald Hoffman, Guido Finazzi, Francisco Cervantes, Jason R. Gotlib, Shireen Sirhan, Jane Apperley, Angélique Langlois, Ying Wan, Laurie Jill Sherman, Souria Dougherty, Faye Feller, Olatoyosi Odenike
Institutions: Mayo Clinic, Leipzig University, AZ Sint-Jan, University of Maryland, Baltimore, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Hôpital Saint-Louis, Université Paris Diderot, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, Ospedale Papa Giovanni XXIII, Hospital Clínic de Barcelona, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Universitat de Barcelona, Stanford Medicine, Stanford University, Jewish General Hospital, Imperial College London, Janssen Research & Development (United States), University of Chicago
Language: English
Subfield: Genetics (clinical)
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2891562335